FCER2 and neoplasm: And in the ligand-receptor interaction, the B cells activation group exhibited more CSF, CXCL, and MHC-I signaling pathway, while CD22, and CD23 was inhibited, indicating that the B cells activation group improved anti-tumor immunity through cell-cell intercommunication (Supplementary Fig. 2g).